These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 21778772

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Managing adverse events in the use of bevacizumab and chemotherapy.
    Blowers E, Hall K.
    Br J Nurs; ; 18(6):351-6, 358. PubMed ID: 19329899
    [Abstract] [Full Text] [Related]

  • 3. Managing patients treated with bevacizumab combination therapy.
    Gordon MS, Cunningham D.
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [Abstract] [Full Text] [Related]

  • 4. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM, Shah SR.
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H, Saini S.
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS.
    J Clin Oncol; 2011 Nov 10; 29(32):4286-93. PubMed ID: 21990397
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.
    Breast Cancer Res Treat; 2010 Jul 10; 122(1):181-8. PubMed ID: 20361252
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D, Sartori S, Papi M, Drudi F, Castellani C, Carloni F, Tombesi P, Lazzari-Agli L.
    Oncology; 2011 Jul 10; 80(5-6):350-8. PubMed ID: 21791945
    [Abstract] [Full Text] [Related]

  • 12. Adverse events in bevacizumab and chemotherapy: patient management.
    Blowers E, Hall K.
    Br J Nurs; 2011 Jul 10; 18(7):424-8. PubMed ID: 19373187
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
    Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW.
    Eur J Cancer; 2011 Nov 10; 47(16):2387-95. PubMed ID: 21757334
    [Abstract] [Full Text] [Related]

  • 14. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J, Gonda A, Szántó J.
    Lege Artis Med; 2008 Oct 10; 18(10):669-73. PubMed ID: 19227609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
    Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F.
    Clin Breast Cancer; 2010 Aug 01; 10(4):307-12. PubMed ID: 20705564
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
    Sini V, Cassano A, Corsi D, De Laurentiis M, Gamucci T, Mauri M, Naso G, Roselli M, Ruggeri EM, Tonini G, Vici P, Zampa G, Marchetti P.
    Tumori; 2016 Oct 13; 102(5):472-480. PubMed ID: 27647231
    [Abstract] [Full Text] [Related]

  • 18. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
    Ge FJ, Xu JM.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 13; 32(7):481-6. PubMed ID: 21029688
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.